Skip to content
Evigrade
ModerateGabapentinoids (antiepileptics)×Angiotensin receptor-neprilysin inhibitor (ARNI)

Updated · Methodology

Mechanism

The documents expect no pharmacokinetic interaction: pregabalin is hardly metabolised and is excreted unchanged by the kidneys (pregabalin SmPC, European Medicines Agency, EMA, sections 4.5 and 5.2), while sacubitril and valsartan depend little on cytochrome P450 enzymes and neither inhibit nor induce them (sacubitril/valsartan SmPC, EMA, section 5.2). The shared risk is angioedema. Both SmPCs describe it (EMA, section 4.4), and the US pregabalin label warns that people taking other drugs associated with angioedema, such as angiotensin-converting enzyme (ACE) inhibitors, may be at increased risk (Lyrica prescribing information, US Food and Drug Administration, FDA, section 5.1). Sacubitril/valsartan is contraindicated with ACE inhibitors precisely because of the angioedema risk (sacubitril/valsartan SmPC, EMA, sections 4.3 and 4.5).

Symptoms

Signs of angioedema include swelling of the face, lips, tongue, gums, throat and larynx. Life-threatening cases with respiratory compromise have been reported (Lyrica prescribing information, US Food and Drug Administration, FDA, section 5.1), and angioedema with laryngeal oedema can be fatal (sacubitril/valsartan SmPC, European Medicines Agency, EMA, section 4.4). Intestinal angioedema with abdominal pain, nausea, vomiting and diarrhoea has also been reported with valsartan (sacubitril/valsartan SmPC, EMA, section 4.4). Pregabalin can cause peripheral oedema and weight gain, and cases of congestive heart failure have been reported in older people with compromised cardiovascular function (Lyrica prescribing information, FDA, sections 5.7 and 5.8; pregabalin SmPC, EMA, section 4.4).

Management

The combination can be used, but the person is told about the signs of angioedema. The US pregabalin label regards people taking other drugs associated with angioedema as being at increased risk (Lyrica prescribing information, US Food and Drug Administration, FDA, section 5.1). At the first signs of angioedema, pregabalin is stopped immediately (pregabalin SmPC, European Medicines Agency, EMA, section 4.4). Sacubitril/valsartan is also stopped immediately, the angioedema is treated, and sacubitril/valsartan is not given again (sacubitril/valsartan SmPC, EMA, section 4.4). Sacubitril/valsartan is used for chronic heart failure (EMA, section 4.1), and pregabalin is used with caution in older people with compromised cardiovascular function (pregabalin SmPC, EMA, section 4.4). Data in NYHA class III–IV heart failure are limited, and the US label also advises caution (FDA, section 5.7). New leg oedema or rapid weight gain is a reason to check whether heart failure is worsening. These reactions may resolve after pregabalin is stopped (pregabalin SmPC, EMA, section 4.4). The documents call for no dose changes. In renal impairment, the pregabalin dose is reduced according to creatinine clearance (pregabalin SmPC, EMA, section 4.2).

Your whole list in one report

Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email

Add more drugs

Medicine list: everything you take in one place →

Sources

Other interactions with Pregabalin